"The mean reduction in WOMAC pain from baseline was 65% and this compares very favourably with the common oral treatments for patients with osteoarthritis of roughly 30% reduction in WOMAC pain from baseline (NSAID's and opioids)." Rennie said the company had a number of important takeaways from the EAP: (i) Paradigm was able to execute on this program, in the USA, during the height of the COVID19 pandemic (on time and on budget); (ii) The EAP used the same batch of Zilosul (iPPS) that will be used in Paradigm's Phase 3 clinical trial as well as using the same pain scoring system (WOMAC); and (iii) All subjects who commenced the program completed it with no dropouts and no serious adverse events reported. "So good safety and outstanding efficacy are very pleasing outcomes as Paradigm prepares for its Phase 3 clinical trial."